Archive \ Volume.14 2023 Issue 1

Role of Interventional Radiology in Management of Hepatocellular Carcinoma: Systematic Review

, , , , ,


The purpose of this study is to analyse and evaluate the function of interventional radiology in such instances by evaluating several elements of each procedure, such as its influence on survival rates, recurrence, tumour response, and complications. The following databases were searched: PubMed, Web of Science, Science Direct, EBSCO, and the Cochrane Library. Using Rayyan QCRI, study papers were screened by title and abstract before being subjected to a full-text evaluation. This review included 13 studies with participants of varying ages and genders; more than half were males. All included studies discussing the role of interventional radiology in hepatoma cases in diagnosis and treatment. We included Sex studies that were systematic reviews; two were randomized controlled, one was a case-control study, one was a prospective study, two were retrospective studies, and one was a pilot study. In the ablation therapy of hepatocellular carcinoma nodules, we determined that microwave ablation had greater complete ablation and lower local tumour growth than radiofrequency ablation. In large tumors (up to 6 cm), mwa is preferred, and cryoablation is preferred in recurrent disease. Because of a lesser heat-sink effect, mwa and cryoablation are preferred to RFA in perivascular disease. Chemoablation can be used in smaller lesions (<3 cm). In intermediate-stage, multifocal lesions (>3), tace, debs, and tare are to be used.

Downloads: 378
Views: 1311

How to cite:
Alhammami QS, Alanazi SNA, Alanazi SMH, Mohammed ARE, Alanazi STA, Alruwaily ZA. Role of Interventional Radiology in Management of Hepatocellular Carcinoma: Systematic Review. Arch Pharm Pract. 2023;14(1):16-22.
Alhammami, Q. S., Alanazi, S. N. A., Alanazi, S. M. H., Mohammed, A. R. E., Alanazi, S. T. A., & Alruwaily, Z. A. (2023). Role of Interventional Radiology in Management of Hepatocellular Carcinoma: Systematic Review. Archives of Pharmacy Practice, 14(1), 16-22.

Download Citation

1.        Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917. doi:10.1002/ijc.25516

2.        N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50(5):1475-83. doi:10.1002/hep.23181

3.        Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52(2):762-73.

4.        Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33(5):437-47. 

5.        Chinnaratha MA, Chuang MY, Fraser RJ, Woodman RJ, Wigg AJ. Percutaneous thermal ablation for primary hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(2):294-301.

6.        Yang B, Zan RY, Wang SY, Li XL, Wei ML, Guo WH, et al. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2015;13:96.

7.        Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015;61(5):1579-90. 

8.        Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373(9664):614-6. 

9.        Jorob TH, Prince AM, EL-gendy SM, Houseini ME. Novel potential therapeutic role of Interleukins 2&12 and taurine combination against human hepatoma cells propagated EX-Vivo. J Adv Pharm Res. 2019;9(3):136-44.

10.      Almalki GH, Rabah S, Said Arafa NM, Bahshwan SM. Immunohistochemical evaluation of the euphorbia inarticulata extract on liver and kidney tissues in hepatocellular carcinoma rats. Pharmacophore. 2022;13(2):33-40.

11.      Groeschl RT, Wong RK, Quebbeman EJ, Tsai S, Turaga KK, Pappas SG, et al. Recurrence after microwave ablation of liver malignancies: a single institution experience. HPB (Oxford). 2013;15(5):365-71. 

12.      Gupta P, Maralakunte M, Kumar-M P, Chandel K, Chaluvashetty SB, Bhujade H, et al. Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis. Eur Radiol. 2021;31(7):5400-8. 

13.      Yeow M, Zhao JJ, Fong KY, Wong J, Tan AYH, Kam JH, et al. Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. World J Surg. 2022;46(11):2778-87. doi:10.1007/s00268-022-06691-x

14.      Dou Z, Lu F, Ren L, Song X, Li B, Li X. Efficacy and safety of microwave ablation and radiofrequency ablation in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore). 2022;101(30):e29321. doi:10.1097/MD.000000000002932

15.      Lu DE, Cheng SW, Lin YS, Tu MW, Lee CH, Chen C, et al. Combination of radiofrequency ablation and percutaneous ethanol injection versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis. Ann Hepatol. 2022;27(5):100729. doi:10.1016/j.aohep.2022.100729

16.      Luo W, Zhang Y, He G, Yu M, Zheng M, Liu L, et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis. World J Surg Oncol. 2017;15(1):126.  doi:10.1186/s12957-017-1196-2

17.      Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P, et al. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol. 2014;21(3):e480-92. doi:10.3747/co.21.1829

18.      Radosevic A, Quesada R, Serlavos C, Sánchez J, Zugazaga A, Sierra A, et al. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. Sci Rep. 2022;12(1):316. doi:10.1038/s41598-021-03802-x

19.      Paul SB, Acharya SK, Gamanagatti SR, Sreenivas V, Shalimar S, Gulati MS. Acetic acid versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A randomized controlled trial. Diagn Interv Imaging. 2020;101(2):101-10. doi:10.1016/j.diii.2019.06.011

20.      Schullian P, Johnston EW, Putzer D, Eberle G, Laimer G, Bale R. Stereotactic radiofrequency ablation of subcardiac hepatocellular carcinoma: a case-control study. Int J Hyperthermia. 2019;36(1):876-85. doi:10.1080/02656736.2019.1648886

21.      Ryu T, Takami Y, Wada Y, Hara T, Sasaki S, Saitsu H. Actual 10-Year Survival After Surgical Microwave Ablation for Hepatocellular Carcinoma: A Single-Center Experience in Japan. Ann Surg Oncol. 2019;26(12):4126-33. doi:10.1245/s10434-019-07646-8

22.      Zheng ZJ, Fu J, Zhi F, Liu WJ, Guo YJ, Zhu DD, et al. The effects of interventional therapy on serum HTATIP2/TIP30, B7-H4 and short-term curative effect in primary hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(20):6778-83.

23.      Peng Y, Cui D, Li W, Ding M, Shi Y, Wang T, et al. Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe: A pilot clinical study. J Cancer Res Ther. 2021;17(3):764-70. 

24.      Pearson AS, Izzo F, Fleming RY, Ellis LM, Delrio P, Roh MS, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg. 1999;178(6):592-9. 

25.      Adam R, Hagopian EJ, Linhares M, Krissat J, Savier E, Azoulay D, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg. 2002;137(12):1332-9.

26.      Huang YZ, Zhou SC, Zhou H, Tong M. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013;60(125):1131-5.

27.      Wang C, Lu Y, Chen Y, Feng Y, An L, Wang X, et al. Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clin Exp Metastasis. 2009;26(7):839-48. 

28.      Tait IS, Yong SM, Cuschieri SA. Laparoscopic in situ ablation of liver cancer with cryotherapy and radiofrequency ablation. Br J Surg. 2002;89(12):1613-9. 

29.      Kurokohchi K, Deguchi A, Masaki T, Yoneyama H, Himoto T, Miyoshi H, et al. Comparative study of the effects of percutaneous ethanol injection and radiofrequency ablation in cases treated with a straight or expandable electrode. Oncol Rep. 2007;18(5):1275-9. 

30.      Ei S, Hibi T, Tanabe M, Itano O, Shinoda M, Kitago M, et al. Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. Ann Surg Oncol. 2015;22(4):1294-300. 

31.      Dunne RM, Shyn PB, Sung JC, Tatli S, Morrison PR, Catalano PJ, et al. Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: a comparison of the safety of cryoablation and radiofrequency ablation. Eur J Radiol. 2014;83(4):632-8. 

32.      Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54(8):1151-6.

33.      Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol. 2003;38(7):770-8. 

34.      Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Treatment of nodular hepatocellular carcinoma larger than 3 cm with ultrasound-guided percutaneous acetic acid injection. Hepatology. 1996;24(6):1379-85. 

35.      Kariyama K, Nouso K, Wakuta A, Kishida M, Nishimura M, Wada N, et al. Percutaneous radiofrequency ablation for treatment of hepatocellular carcinoma in the caudate lobe. AJR Am J Roentgenol. 2011;197(4):W571-5.

36.      Pan T, Li XS, Xie QK, Wang JP, Li W, Wu PH, et al. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. Clin Radiol. 2014;69(12):e553-61.

37.      Jin S, Fu Q, Wuyun G, Wuyun T. Management of post-hepatectomy complications. World J Gastroenterol. 2013;19(44):7983-91.

38.      Mardi K, Sarohi M. Hepatoid adenocarcinoma of gallbladder: A mimicker of hepatocellular carcinoma. Clin Cancer Investig J. 2021;10(6):333-5.

39.      Bruix J, Sherman M. AASLD Practice Guideline. Management of hepatocellular carcinoma. Hepatology. 2011;53:1020-2. doi:10.1002/hep.20933

40.      Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158.

41.      van Tilborg AA, Scheffer HJ, de Jong MC, Vroomen LG, Nielsen K, van Kuijk C, et al. MWA Versus RFA for Perivascular and Peribiliary CRLM: A Retrospective Patient- and Lesion-Based Analysis of Two Historical Cohorts. Cardiovasc Intervent Radiol. 2016;39(10):1438-46. 

42.      Vogl TJ, Nour-Eldin NA, Hammerstingl RM, Panahi B, Naguib NNN. Microwave Ablation (MWA): Basics, Technique and Results in Primary and Metastatic Liver Neoplasms - Review Article. Rofo. 2017;189(11):1055-66.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.